Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. (November 2014)

• Record Type: Journal Article
• Authors: Singh, Satnam; Beadle, Roger; Cameron, Donnie; Rudd, Amelia; Bruce, Maggie; Jagpal, Baljit; Schwarz, Konstantin; Brindley, Gemma; Mckiddie, Fergus; Lang, Chim; Dawson, Dana; Frenneaux, Michael
• Is Part Of: Future cardiology. Volume 10:Number 6(2014)
• Page Start: 693
• Page End: 698
• Publication Date: 2014-11
• Subjects: cardiac spectroscopy -- diastole -- ejection fraction -- heart failure -- perhexiline; Cardiology -- Research -- Periodicals; 616.12005
• DOI: 10.2217/fca.14.62
• Languages: English
• ISSNs: 1479-6678

Abstract

ABSTRACT : Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.